Ricevi le ultime notizie sulle azioni Mesoblast con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MESO

Ultime notizie per

Mesoblast

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

Health Care

Press Releases

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Earnings

Successful Commercial Launch of Ryoncil®

News

Mesoblast Financial Results and Corporate Update Webcast

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Markets

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

General

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

ADIA

CRSP

FATE

LCTX

MESO

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Biohaven

Celcuity

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Cogent Biosciences

Denali Therapeutics

Dyne Therapeutics

89bio

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

ImmunityBio

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

MannKind

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Piper Sandler

Maxim Group

Chardan Capital

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

BCLI

BRTX

LGVN

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Comments

Mesoblast Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO